



GANYMED scientists receive Georges-Köhler Award

Mainz, Germany – September 21, 2005 – GANYMED Pharmaceuticals AG is proud to announce receipt of the Georges-Köhler Award of the German society for immunology by GANYMED's founders and leading scientists Drs. Özlem Türeci and Ugur Sahin for their outstanding work on the development of new immunologic approaches in the fight against cancer.

For the first time, the methods developed by the award winners made a systematic mapping of spontaneous immune responses in cancer patients possible. In collaboration with the University of Mainz, GANYMED is using these proprietary methods to identify truly cancer specific structures ("Targets"), only found in tumors and not in healthy tissues. The knowledge of such structures is the prerequisite for the development of efficient therapies against cancer.

"We are proud that Özlem and Ugur have been honored with this prestigious award for their ground breaking work in cancer immunology", Dr. Rainer Wessel, President and CEO of GANYMED emphasized the significance of this award. "Their outstanding achievements have significantly fostered the development of GANYMED's highly efficient antibody cancer therapies."

GANYMED Pharmaceuticals AG is building a sustainable pipeline of monoclonal antibody therapeutics against solid tumors, where current therapies are poor and where there is an overriding medical need. The therapeutic efficacy of current solid cancer therapeutics is severely limited, because their molecular targets are elevated in a subset of a particular cancer but they are also found widely in normal tissues. In contrast, GANYMED's pan cancer surface antigens are uniquely specific for cancer tissues and can be expected to show greater therapeutic efficacy and better safety allowing significant reduction in time to market. The Company will market its cancer therapeutics after clinical or animal proof of concept has been demonstrated to large pharmaceutical and biotech companies.

Downloads: Text as rtf-file in „Presse Pool“: www.biocommunications.net

For further inquiries / contact:

GANYMED Pharmaceuticals AG
Dirk L. Sebastian, CFO/COO
Freiligrathstrasse 12
55131 Mainz, Germany
phone: (+49) 6131 / 1440 100
fax: (+49) 6131 / 1440 114
email: info@ganymed-pharmaceuticals.com